论文部分内容阅读
目的 :了解原癌基因bcl 6在一组淋巴组织增生性疾病中表达情况 ,探讨弥漫性大B细胞淋巴瘤的发病机制和bcl 6表达在鉴别诊断中的意义。方法 :观察 112例淋巴组织增生性疾病的组织病理学形态及分型和检测bcl 6表达。结果 :9例淋巴结反应性增生的生发中心细胞、12例滤泡性淋巴瘤和 16例中心细胞中心母细胞淋巴瘤的肿瘤细胞均可表达bcl 6 ,表达强度多为弱阳性 ,阳性率和阳性强度差别无统计学意义 (P >0 0 5 ) ;6 0例弥漫性大B细胞淋巴瘤表达阳性率 95 % ,表达强度为中等阳性或强阳性 ,与前一组相比差别有统计学意义 (P <0 0 1) ;5例套细胞淋巴瘤 ,6例典型霍奇金淋巴瘤及 4例外周T细胞淋巴瘤均不表达bcl 6。结论 :弥漫性大B细胞淋巴瘤显著表达bcl 6 ,表达强度高于淋巴结反应性增生、滤泡性淋巴瘤和中心细胞中心母细胞淋巴瘤 ,bcl 6的过度表达可能与其发病有关。bcl 6的表达对反应性增生和滤泡性淋巴瘤的鉴别诊断无意义 ,但对滤泡性淋巴瘤和弥漫性大B细胞淋巴瘤的鉴别有辅助作用。
OBJECTIVE: To investigate the expression of bcl-6 in a group of lymphoproliferative diseases and to explore the pathogenesis of diffuse large B-cell lymphoma and the significance of bcl-6 expression in the differential diagnosis. Methods: Histopathological features and classification of 112 cases of lymphoproliferative diseases were observed and the expression of bcl-6 was detected. Results: Nine cases of germinal center cells with lymph node reactive hyperplasia, 12 cases of follicular lymphoma and 16 cases of centroblastic lymphoma tumor cells could express bcl-6, the expression intensity was weakly positive, the positive rate and positive There was no significant difference between the two groups (P> 0.05). The positive rate of diffuse large B cell lymphoma in 60 cases was 95%, and the expression intensity was moderately positive or strongly positive, which was significantly different from the former group (P <0.01); 5 cases of mantle cell lymphoma, 6 cases of Hodgkin’s lymphoma and 4 cases of peripheral T cell lymphoma did not express bcl 6. CONCLUSION: Bcl-6 is highly expressed in diffuse large B-cell lymphoma and its expression intensity is higher than that in lymph node-responsive hyperplasia. The overexpression of bcl-6 may be related to follicular lymphoma and centroblastic lymphoma. The expression of bcl-6 is of no significance for the differential diagnosis of reactive hyperplasia and follicular lymphoma, but it is also an aid in the differential diagnosis of follicular lymphoma and diffuse large B-cell lymphoma.